News >

FDA Accepts sBLA for Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC

Gina Columbus @ginacolumbusonc
Published: Thursday, Jan 17, 2019

Dr. Sandra Horning
Sandra Horning, MD
The FDA has accepted a supplemental biologics license application (sBLA) for atezolizumab (Tecentriq), carboplatin, and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication